Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Why should I use sharewise

Novus Therapeutics Inc. Stock

Price
Target price
€0.41

€0.41

-10.100%
-0.026
-10.100%
-

-

 
Latest predictions
-
02.06.20
buy
Your prediction

Novus Therapeutics Inc. Stock

Heavy losses for Novus Therapeutics Inc. today as the stock fell by -€0.026 (-10.100%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Novus Therapeutics Inc. stock is not clear.
Register To Post

Other discussions about Novus Therapeutics Inc. Stock

New thread

News

Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced topline results

Novus Therapeutics Reports First Quarter 2020 Financial Results


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial

Novus Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced financial

Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced that it has

Novus Therapeutics Provides Update on OP0201


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the

Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds


Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the